Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 6,313 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advanced therapy Clear all

Conditions: Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
Interventions: afatinib dimaleate, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Decatur, Illinois + 3 more

Conditions: Advanced BRAF Mutant Cancers
Interventions: Binimetinib, Encorafenib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Adenocarcinoma of Lung
Interventions: JNJ-64041757, Nivolumab; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Nashville, Tennessee • Spokane, Washington

Conditions: Polycystic Ovary Syndrome, Vitamin D Deficiency
Interventions: Vitamin D3; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 16 Years to 48 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions: Ad5CMV-p53 gene; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy; Radiation · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more

Conditions: Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV, Cervical Cancer Stage IIIB, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB, Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Vulvar Cancer, Stage III, Vulvar Cancer, Stage IV, Vaginal Cancer Stage III, Vaginal Cancer Stage IVA, Vaginal Cancer Stage IVB
Interventions: Strong Together serious game; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Cancer
Interventions: cetuximab; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 157
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more

Conditions: Neonatal Encephalopathy
Interventions: Enteral Feeding; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 0 Days to 2 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: suramin, paclitaxel, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Solid Tumors
Interventions: Bevacizumab, Everolimus and LBH589; Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab; Drug
Lead sponsor: NeoTX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Daphne, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more

Conditions: Breast Cancer
Interventions: Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatitis B Virus Infection
Interventions: Flavonoid, Tenofovir; Drug
Lead sponsor: Trieu, Nguyen Thi, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions: CM-24 (MK-6018), Pembrolizumab (MK-3475); Biological
Lead sponsor: Famewave Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • New Haven, Connecticut

Conditions: Advanced Solid Tumor
Interventions: MSC2015103B; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Breast Cancer
Interventions: Lapatinib, Letrozole, Trastuzumab; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions: Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 11
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions: Ivosidenib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions: DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy; Biological · Radiation · Drug
Lead sponsor: DEKA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676 + Erlotinib, Erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 35
States / cities: Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Hematologic Neoplasms
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 19
States / cities: Duarte, California • Stanford, California • Aurora, Colorado + 14 more

Search by objective public record fields.

Afatinib in Advanced Refractory Urothelial Cancer

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Self-Advocacy Serious Game in Advanced Cancer

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)

Feasibility of Semaglutide in Advanced Lung Disease

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

MSC2015103B in Solid Tumors

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation